| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate |
2014-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2016-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2016518368-A |
| titleOfInvention |
Antibodies that can specifically bind to HER2 |
| abstract |
The present invention relates to a HER2 (human epidermal growth factor receptor 2) antibody for the prevention or treatment of cancer. The antibody of the present invention specifically binds to HER2 that is overexpressed in cancer cells (particularly breast cancer cells and gastric cancer cells) and specifically binds to an epitope on HER2 that is different from the epitope for trastuzumab. The CDR sequences of the antibodies of the present invention show low similarity to the CDR sequences of known HER2 antibodies, indicating that the CDR sequences are unique. The antibody and trastuzumab combination of the present invention kills cancer cells with significantly enhanced cytotoxicity and is therefore very effective in the treatment of cancer (particularly breast and gastric cancer). Without being bound by theory, the enhanced effect of the combination therapy is that the antibodies of the present invention bind to an epitope on HER2 that is different from the epitope for trastuzumab and cooperate with trastuzumab to inhibit HER2. Can show. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11459394-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021509288-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7132232-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11649294-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020508334-A |
| priorityDate |
2013-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |